FacebookTwitterGoogle+RedditEmail

Pharma Paid and Trump Delivered


How high are Pharma’s prices? Novartis wants $475,000 a patient for its new cancer therapy. Hep C drugs cost $95,000 for a course of treatment. The immune drug, Actimmune, costs $52,321.80 a month. The parasite drug Daraprim costs $45,000 a month. And the gallstone drug Chenodal costs $42,570 a month.

But this week in his long-awaited speech, Trump blamed foreign countries for high drug prices in the US and reversed his campaign pledge to use Medicare’s buying power to negotiate lower drug prices. Pharma stock prices rose; the shilling paid off.

Pharma has two lobbyists for every member of Congress. It spends more on lobbying than tobacco, oil and defense contractors combined. It parades patients before public and consumer panels to “provide media outlets a human face to attach to a cause when insurers balk at reimbursing patients for new prescription medications,” writes Melissa Healy of the Los Angeles Times.

And that is not enough for Pharma. Companies also try to incorporate in the UK, Ireland and other overseas locations to dodge the US taxes that fund them such as Medicare. They already manufacture and test drugs overseas because the labor is cheap.

The US government is captured. Pharma operatives head both Health and Human Services and the FDA. The CDC Foundation which receives millions from corporations (not that it affects policies or anything) lists as donors Abbott, AbbVie, Bayer, AstraZeneca, Merck, Pfizer, GlaxoSmithKline Biologicals, Eli Lilly, Amgen, Genentech, Gilead and many more. (Is that why the CDC allows its name to be used in Gilead ads for its Hep C drug?)

Until 2010, PhRMA, Pharma’s top lobbying group, was headed by former Louisiana Rep. Billy Tauzin who resigned from Congress where he chaired the committee which oversees the drug industryonly to immediately reappear as the leader of PhRMA where he drew a $2 million salary. No conflict of interest there.

Tauzin had played a key role in shepherding the Medicare Prescription Drug Bill through Congress which prohibited government negotiation of lower drug prices and Canadian imports. “It’s a sad commentary on politics in Washington that a member of Congress who pushed through a major piece of legislation benefiting the drug industry, gets the job leading that industry,” Public Citizen’s President Joan Claybrook said.

Two-thirds of Pharma lobbyists previously worked for Congress or federal agencies reports the New York Times. An aide to former Michigan Rep. John D. Dingell now works for PhRMA, and an aide to former Iowa Sen. Tom Harkin, who was the chairman of the Senate health committee “is now a top lobbyist for Merck.” Gary Andres, former staff director of the House Energy and Commerce Committee now lobbies for biotech companies. And the list goes on.

Having captured Congress, you wouldn’t think Pharma would need a charm offensive. Yet it spends millions trying to convince the public it has our interests at heart as it raises our taxes and health care costs. Currently, “America’s Biopharmaceutical companies” are running their “Go Boldly” campaign, ennobling their work with the pay-off line “here’s to permission to fail.”

Yes, Pharma knows a lot about “permission to fail.” Over 20 of its drugshave been withdrawn from the market in recent years because they were so dangerous—-after maximum money was made of course. They include Vioxx, Bextra, Baycol, Trovan, Meridia, Seldane, Hismanal, Darvon, Raxar, Redux Mylotarg, Lotronex, Propulsid, phenylpropanolamine (PPA), Prexige, phenacetin, Oraflex, Omniflox, Posicor, Serzone and Duract.

Pharma also runs a sappy “Hope to Cures: The Value of Biopharmaceutical Innovation and New Drug Discovery” campaign that showcases patients whose lives were saved by expensive drugs. “If you object to our six-digit drug prices you are signing the death warrant for these patients,” the sleazy campaign seeks to convey.

Two lies lurk under the PR stunt. First, most of Pharma’s profits come from non life-savingdrugs that treat acid reflux, ADHD, poor eating habits and a host of  trumped up psychiatric illnesses. Secondly, research accounts for only one-fifth of Pharma’s drug costs. Most drug costs Pharma seeks to recoup are for marketing––the ask-your-doctor ads you see on TV––and, of course, lobbying.

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

November 13, 2018
Patrick Cockburn
The Midterm Results are Challenging Racism in America in Unexpected Ways
Victor Grossman
Germany on a Political Seesaw
Cillian Doyle
Fictitious Assets, Hidden Losses and the Collapse of MDM Bank
Lauren Smith
Amnesia and Impunity Reign: Wall Street Celebrates Halliburton’s 100th Anniversary
Joe Emersberger
Moreno’s Neoliberal Restoration Proceeds in Ecuador
Carol Dansereau
Climate and the Infernal Blue Wave: Straight Talk About Saving Humanity
Dave Lindorff
Hey Right Wingers! Signatures Change over Time
Dan Corjescu
Poetry and Barbarism: Adorno’s Challenge
Patrick Bond
Mining Conflicts Multiply, as Critics of ‘Extractivism’ Gather in Johannesburg
Ed Meek
The Kavanaugh Hearings: Text and Subtext
Binoy Kampmark
Concepts of Nonsense: Australian Soft Power
November 12, 2018
Kerron Ó Luain
Poppy Fascism and the English Education System
Conn Hallinan
Nuclear Treaties: Unwrapping Armageddon
Robert Hunziker
Tropical Trump Declares War on Amazonia
John W. Whitehead
Badge of Shame: the Government’s War on Military Veterans
Will Griffin
Military “Service” Serves the Ruling Class
John Eskow
Harold Pinter’s America: Hard Truths and Easy Targets
Rob Okun
Activists Looking Beyond Midterm Elections
Binoy Kampmark
Mid-Term Divisions: The Trump Take
Dean Baker
Short-Term Health Insurance Plans Destroy Insurance Pools
George Wuerthner
Saving the Buffalohorn/Porcupine: the Lamar Valley of the Gallatin Range
Patrick Howlett-Martin
A Note on the Paris Peace Forum
Joseph G. Ramsey
Does America Have a “Gun Problem”…Or a White Supremacy Capitalist Empire Problem?
Weekend Edition
November 09, 2018
Friday - Sunday
Louis Proyect
Why Democrats Are So Okay With Losing
Andrew Levine
What Now?
Jeffrey St. Clair
Roaming Charges: Chuck and Nancy’s House of Cards
Brian Cloughley
The Malevolent Hypocrisy of Selective Sanctions
Marc Levy
Welcome, Class of ‘70
David Archuleta Jr.
Facebook Allows Governments to Decide What to Censor
Evaggelos Vallianatos
The Zika Scare: a Political and Commercial Maneuver of the Chemical Poisons Industry
Nick Pemberton
When It Comes To Stone Throwing, Democrats Live In A Glass House
Ron Jacobs
Impeach!
Lawrence Davidson
A Tale of Two Massacres
José Tirado
A World Off Balance
Jonah Raskin
Something Has Gone Very Wrong: An Interview With Ecuadoran Author Gabriela Alemán
J.P. Linstroth
Myths on Race and Invasion of the ‘Caravan Horde’
Dean Baker
Good News, the Stock Market is Plunging: Thoughts on Wealth
David Rosen
It’s Time to Decriminalize Sex Work
Dan Glazebrook
US Calls for a Yemen Ceasefire is a Cynical Piece of Political Theatre
Jérôme Duval
Forced Marriage Between Argentina and the IMF Turns into a Fiasco
Jill Richardson
Getting Past Gingrich
Dave Lindorff
Not a Blue Wave, But Perhaps a Foreshock
Martha Rosenberg
Dangerous, Expensive Drugs Aggressively Pushed? You Have These Medical Conflicts of Interest to Thank
Will Solomon
Not Much of a Wave
Nicolas J S Davies
Why Yemeni War Deaths are Five Times Higher Than You’ve Been Led to Believe
FacebookTwitterGoogle+RedditEmail